Barrons
23 Oct 2026, 08:09 UTC · 2h ago
U.S. Treasury Wants to Rein In Deals for Chinese Biotech and AI
Impact · against what's priced in
U.S. Treasury restrictions on Chinese biotech and AI investments create a headwinds for pharmaceutical companies by limiting access to external oncology pipelines. This likely increases long-term R&D costs and domestic acquisition premiums, though the market has already begun discounting these geopolitical risks.
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
